ImmunoCellular Therapeutics to present at Biotech Industry Conference

ImmunoCellular Therapeutics (OTCBB:IMUC), said Wednesday that president and CEO Manish Singh will be presenting at the 19th Annual Future Leaders Biotech Industry Conference in the Millennium Broadway Hotel & Conference Center in New York City.
ImmunoCellular will be presenting on Friday, April 20th, at 2:30 pm EST in presentation room 302/303.
The Annual Future Leaders in the Biotech Industry Conference brings the industry’s top financial professionals together with an agenda designed to meet the current investment climate.
Presenting companies will showcase their science, detail their unpartnered assets and upcoming milestones.
IMUC’s lead product candidate ICT-107 is currently in a randomized phase II trial at multiple centres in the U.S. ICT-107 is a dendritic cell-based vaccine targeting multiple tumour-related antigens for glioblastoma, a malignant brain tumour.
This is done by removing dendritic cells from a patient, loading them with the tumour-related antigens, and re-injecting them back into the patient's body to trigger an immune response against cancer cells exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen, IMUC’s vaccine tracks multiple different antigens found on cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour cells, and lead to cancer’s re-growth after chemotherapy. It is believed that destroying the cancer stem cells will allow for longer survival, without relapse.